Thiazolidinediones: Beyond glycemic control

Treatments in Endocrinology

Volumn 5, Issue 1, 2006, Pages 25-36

  Reynolds, Kathryn ^a   Goldberg, Ronald B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBUMIN; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIGLITAZONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LIPOPROTEIN; METFORMIN; PIOGLITAZONE; PRAVASTATIN; RAMIPRIL; ROSIGLITAZONE; SULFONYLUREA; TOCOPHEROL; TROGLITAZONE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADIPOGENESIS; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERY WALL; ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD PRESSURE; BLOOD VESSEL INJURY; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; FOAM CELL; FOREARM; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; MACROPHAGE; METABOLIC SYNDROME X; MICROALBUMINURIA; MICROANGIOPATHY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOOTH MUSCLE; STEATOSIS; URINARY EXCRETION; VASCULAR DISEASE; GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; THIAZOLIDINEDIONES;

EID: 30744471644     PISSN: 11756349     EISSN: 11756349     Source Type: Journal    
DOI: 10.2165/00024677-200605010-00004     Document Type: Review

References (138)

1. Takano H, Komuro I. Roles of peroxisome proliferator-activated receptor gamma in cardiovascular disease. J Diabetes Complications 2002; 16: 108-14
2. Chinetti-Gbaguidi G, Fruchart J, Staels B. Role of the PPAR family of receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy. Curr Opin Pharmacol 2005; 5: 177-83
3. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-18
4. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 2000; 129: 823-34
5. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003; 144: 5159-65
6. Kunhiraman B, Jawa A, Fonseca V. Potential cardiovascular benefits of insulin sensitizers. Endocrinol Metab Clin North Am 2005; 34: 117-35
7. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre, randomized, placebo-controlled trial. Lancet 2004; 364: 685-96
8. Alexander CM, Landsman PB, Teutsch SM, et al. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP): NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants aged 50 years and older. Diabetes 2003; 52: 1210-4
9. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28
10. Plutzky J. The vascular biology of atherosclerosis. Am J Med 2003; 115 (8A): 55S-61S
11. Ritchie SA, Ewart MA, Perry CG, et al. The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin Sci (Lond) 2004; 107: 519-32
12. Bierhaus A, Schiekofer S, Schwaninger M, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50: 2792-808
13. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7
14. Shankar SS, Steinberg HO. FFAs: do they play a role in vascular disease in the insulin resistance syndrome? Curr Diab Rep 2005; 5: 30-5
15. Venugopal SK, Devaraj S, Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005; 14: 33-7
16. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-808
17. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005; 25: 2062-8
18. Caballero A, Saouaf R, Lim S, et al. The effects of troglitazone, an insulinsensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 2003; 52: 173-80
19. Pistrosch F, Passauer J, Fischer S, et al. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004; 27: 484-90
20. Tack CJ, Ong MK, Lutterman JA, et al. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance: effects of troglitazone. Diabetologia 1998; 41: 569-76
21. Moroe H, Fujii H, Honda H, et al. Characterization of endothelium-dependent relaxation and modulation by treatment with pioglitazone in the hypercholesterolemic rabbit renal artery. Eur J Pharmacol 2004; 497: 317-25
22. Calnek DS, Mazzella L, Roser S, et al. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 52-7
23. Satoh H, Tsukamoto K, Hashimoto Y, et al. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function. Biochem Biophys Res Commun 1999; 254: 757-63
24. Martin-Nizard F, Furman C, Delerive P, et al. Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J Cardiovasc Pharmacol 2002; 40: 822-31
25. Cominacini L, Garbin U, Pasini AF, et al. The expression of adhesion molecules on endothelial cells is inhibited by troglitazone through its antioxidant activity. Cell Adhes Commun 1999; 7: 223-31
26. Ghanim H, Garg R, Aljada A, et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential anti-atherosclerotic effect in the obese. J Clin Endocrinol Metab 2001; 86: 1306-12
27. Imamoto E, Yoshida N, Uchiyama K, et al. Inhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cells. Biofactors 2004; 20: 37-47
28. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent anti-inflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004; 89: 2728-35
29. Jiang C, Ting A, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-6
30. Wellen KE, Uysal KT, Wiesbrock S, et al. Interaction of tumor necrosis factor-alpha and thiazolidinedione-regulated pathways in obesity. Endocrinology 2004; 145: 2214-20
31. Da Ros R, Assaloni R, Ceriello A. The preventive anti-oxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance. Diabet Med 2004; 21: 1249-52
32. Bagi Z, Koller A, Kaley G. PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with type 2 diabetes. Am J Physiol Heart Circ Physiol 2004; 286: H742-8
33. Garg R, Kumbkarni Y, Aljada A, et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension 2000; 36: 430-5
34. Adachi T, Inoue M, Hara H, et al. Relationship of plasma extracellular-superoxide dismutase level with insulin resistance in type 2 diabetic patients. J Endocrinol 2004; 181: 413-7
35. Marx N, Walcher D, Ivanova N, et al. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 2004; 53: 2662-8
36. Chu NV, Kong AP, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 2002; 25: 542-9
37. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-84
38. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003; 26: 2493-9
39. Lagathu C, Bastard JP, Auclair M, et al. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 2003; 311: 372-9
40. Morrow DA, Ridker PM. C-reactive protein, inflammation, and coronary risk. Med Clin North Am 2000; 84: 149-61
41. Wang TD, Chen WJ, Lin JW, et al. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2004; 93: 362-5
42. Hetzel J, Balletshofer B, Rittig K, et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 2005; 25: 1804-9
43. Verma S, Wang CH, Weisel RD, et al. Hyperglycemia potentiates the proathero-genic effects of C-reactive protein: reversal with rosiglitazone. J Mol Cell Cardiol 2003; 35: 417-9
44. Ouchi N, Kihara S, Funahashi T, et al. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003; 14: 561-6
45. Varo N, Vincent D, Libby P, et al. Elevated plasma levels of the atherogenic mediator soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003; 107: 1954-7
46. Marx N, Imhof A, Froehlich J, et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003; 107: 1954-7
47. Sumita C, Maeda M, Fujio Y, et al. Pioglitazone induces plasma platelet activating factor-acetylhydrolase and inhibits platelet activating factor-mediated cytoskeletal reorganization in macrophage. Biochim Biophys Acta 2004; 1673: 115-21
48. Tontonoz P, Nagy L, Alvarez JG, et al. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93: 241-52
49. Chawla A, Boisvert WA, Lee CH, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001; 7: 161-71
50. Zhang L, Chawla A. Role of PPARgamma in macrophage biology and atherosclerosis. Trends Endocrinol Metab 2004; 15: 500-5
51. Liang CP, Han S, Okamoto H, et al. Increased CD36 protein as a response to defective insulin signaling in macrophages. J Clin Invest 2004; 113: 764-73
52. Bruemmer D, Blaschke F, Law RE. New targets for PPARgamma in the vessel wall: implications for restenosis. Int J Obes Relat Metab Disord 2005; 29 Suppl. 1: S26-30
53. Redondo S, Ruiz E, Santos-Gallego CG, et al. Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator- activated receptor-gamma, transforming growth factor-beta1, and a Smad2-dependent mechanism. Diabetes 2005; 54: 811-7
54. Chen K, Chen J, Li D, et al. Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone. Hypertension 2004; 44: 655-61
55. Calkin AC, Forbes JM, Smith CM, et al. Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol 2005; 25: 1903-9
56. Diep QN, El Mabrouk M, Cohn JS, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002; 105: 2296-302
57. Takeda K, Ichiki T, Tokunou T, et al. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 2005; 102: 1834-9
58. Ferrario CM. Use of angiotensin II receptor blockers in animal models of atherosclerosis. Am J Hypertens 2002; 15: 9S-13S
59. Marx N, Froelich J, Siam L, et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 283-8
60. Sidhu J, Cowan D, Tooze J, et al. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. Am Heart J 2004; 147: 1032-7
61. Li D, Chen K, Sinha N, et al. The effects of PPARγ ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res 2005; 65: 907-12
62. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003; 42: 1764-6
63. Zirlik A, Leugers A, Lohrmann J, et al. Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thromb Haemost 2004; 91: 674-82
64. Liu HB, Hu YS, Medcalf RL, et al. Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation. Biochem Biophys Res Commun 2005; 334: 30-7
65. Kanehara H, Tohda G, Oida K, et al. Thrombomodulin expression by THP-1 but not by vascular endothelial cells is upregulated by pioglitazone. Thromb Res 2002; 108: 227-34
66. Akbiyik F, Ray DM, Gettings KF, et al. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 2004; 104: 1361-8
67. Shiomi M, Ito T, Tsukada T, et al. Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits. Atherosclerosis 1999; 142: 345-53
68. Chen Z, Ishibashi S, Perrey S, et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 2001; 21: 372-7
69. Collins AR, Meehan WP, Kintscher U, et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 365-71
70. Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000; 106: 523-31
71. Claudel T, Leibowitz MD, Fievet C, et al. Reduction of atherosclerosis in apoli-poprotein-E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci U S A 2001; 98: 2610-5
72. Levi Z, Shaish A, Yacov N, et al. Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model. Diabetes Obes Metab 2003; 5: 45-50
73. Clough MH, Schneider DJ, Sobel BE, et al. Attenuation of accumulation of neointimal lipid by pioglitazone in mice genetically deficient in insulin receptor substrate-2 and apolipoprotein E. J Histochem Cytochem 2005; 53: 603-10
74. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-14
75. Boden G, Homko C, Mozzoli M, et al. Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 2005; 54: 880-5
76. Unger RH. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 2003; 14: 398-403
77. Schadinger SE, Bucher NL, Schreiber BM, et al. PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab 2005; 288: E1195-205
78. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-91
79. Petersen KF, Shulman GI. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 11G-8G
80. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 2003; 38: 434-40
81. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39: 188-96
82. Siegel R, Cupples A, Schaefer E, et al. Lipoproteins, apolipoproteins, and low density lipoprotein size among diabetics in the Framingham offspring study. Metabolism 1996; 45: 1267-72
83. Del Pilar Solano M, Goldberg RB. Management of diabetic dyslipidemia. Endocrinol Metab Clin North Am 2005; 34: 1-25
84. Van Wijk JP, de Koning EJ, Martens EP, et al. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003; 23: 1744-9
85. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164: 2097-104
86. Goldberg RB, Kendall D, Deeg M, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-54
87. Wagner JA, Larson PJ, Weiss S, et al. Individual and combined effects of peroxisome proliferator-activated receptor gamma agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers. J Clin Pharmacol 2005; 45: 504-13
88. Nagashima K, Lopez C, Donovan D, et al. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2005; 115: 1323-32
89. Lewis GF, Murdoch S, Uffelman K, et al. Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglita-zone. Diabetes 2004; 53: 2893-900
90. Bogacka I, Xie H, Bray GA, et al. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 2005; 54: 1392-9
91. Natali A, Ferrannini E. Hypertension, insulin resistance, and the metabolic syndrome. Endocrinol Metab Clin North Am 2004; 33: 417-29
92. Raji A, Seely E, Bekins S, et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26 (1): 172-8
93. Sarafidis P, Lasaridis A, Nilsson P, et al. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlated with insulin sensitivity increase. J Hypertens 2004; 22: 1769-77
94. Fullert S, Schneider F, Haak E, et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002; 87: 5503-6
95. Ryan MJ, Didion SP, Mathur S, et al. PPAR (gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 2004; 43: 661-6
96. Nicol CJ, Adachi M, Akiyama TE, et al. PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am J Hypertens 2005; 18: 549-56
97. Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998; 21: 2135-9
98. Nakamura T, Ushiyama C, Osada S, et al. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001; 50: 1193-6
99. Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes, J Hum Hypertens 2003; 17: 7-12
100. Sarafidis P, Lasaridis A, Nilsson P, et al. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am J Hypertens 2005; 18: 227-34
101. Stephens TW, Bergman JA, Bue-Valleskey JM, et al. Thiazolidinedione induced cardiac biochemical changes and increased IGF-1 action on cardiomyocytes [abstract]. Diabetologia 1995; 38: A200
102. Breider MA, Gough AW, Haskins JR, et al. Troglitazone-induced heart and adipose tissue cell proliferation in mice. Toxicol Pathol 1999; 27: 545-52
103. Young LH. Insulin resistance and the effects of thiazolidinediones on cardiac metabolism. Am J Med 2003; 115 Suppl. 8A: 75S-80S
104. Ghazzi M, Perez J, Antonucci T, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM: the Troglitazone Study Group. Diabetes 1997; 46: 433-9
105. Asakawa M, Takano H, Nagai T, et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002; 105: 1240-6
106. St John S, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25: 2058-64
107. Scherbaum WA, Goke B. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res 2002; 34: 589-95
108. Young LH. The patient with diabetes mellitus and heart failure: at-risk issues. Am J Med 2003; 115 Suppl. 8A: 107S-10S
109. Zhu P, Lu L, Xu Y, et al. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation 2000; 101: 1165-71
110. Yue T, Bao W, Gu J, et al. Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005; 54: 554-62
111. Shiomi T, Tsutsui H, Hayashidani S, et al. Pioglitazone, a PPAR gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 106: 3126-32
112. Xu Y, Gen M, Lu L, et al. PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol 2005; 288: H1314-23
113. Murakami T, Mizuno S, Ohsato K, et al. Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus. Am J Cardiol 1999; 84: 92-4
114. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128: 262-9
115. Rajaram V, Pandhya S, Patel S, et al. Role of surrogate markers in assessing patients with diabetes mellitus and the metabolic syndrome and in evaluating lipid-lowering therapy. Am J Cardiol 2004; 93: 32C-48C
116. Xiang A, Peters R, Kjos S, et al. Effect of thiazolidinedione treatment of progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 1986-91
117. Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83: 1818-20
118. Koshiyama H, Shimono D, Kuwamura N, et al. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-6
119. Sidhu J, Kaposzta Z, Markus H, et al. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004; 24: 930-4
120. Kornowski R, Mintz G, Kent K. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia: a serial intra-vascular ultrasound study. Circulation 1997; 95: 1366-9
121. Takagi T, Akasaka T, Yamamuro A. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 2000; 36: 1529-35
122. Takagi T, Yamamuro A, Tamita K. Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 2002; 89: 318-22
123. Takagi T, Yamamuro A, Tamita K, et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003; 146 (2): 1-8
124. Choi D, Kim S, Choi S, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27 (11): 2654-60
125. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89
126. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia 2005; 48: 1726-35
127. Gerstein HC, Yusuf S, Holman R, et al. Rationale, design, and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004; 47: 1519-27
128. Sobel B, Frye R, Detre K. Burgeoning dilemmas is the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI2D) trial. Circulation 2003; 107: 636-42
129. Pershadsingh H. Peroxisome proliferators-activated receptor-γ: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin Investig Drugs 2004; 13: 215-28
130. Palakurthi S, Aktas H, Grubissich L, et al. Anticancer effects of thiazolidinediones are independent of peroxisome proliferators-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res 2001; 61: 6213-8
131. Ferruzzi P, Ceni E, Tarocchi M, et al. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab 2005; 90: 1332-9
132. Panigrahy D, Shen L, Kieran M, et al. Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Investig Drugs 2003; 12: 1925-37
133. Storer P, Xu J, Chavis J, et al. Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J Neuroimmunol 2005; 161: 113-22
134. Ehrmann D. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-36
135. Glueck C, Papanna R, Wang P, et al. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003; 52: 908-15
136. Ghazeeri G, Kutteh W, Bryer-Ash M, et al. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003; 79: 562-6
137. Belli S, Graffigna M, Oneto A, et al. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 2004; 81: 624-9
138. Romualdi D, Guido M, Ciampelli M, et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinemic obese patients with polycystic ovary syndrome. Hum Reprod 2003; 18: 1210-8